FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

The Implications of a Biological Definition of Parkinson’s Disease on Preclinical Research

The Implications of a Biological Definition of Parkinson’s Disease on Preclinical Research

By | 17 September 2025

Examine the impact of biological definitions of Parkinson’s disease on clinical trial design
Investigate the role of emerging biomarkers in the early detection, monitoring of disease progression, and assessment of therapeutic efficacy in Parkinson’s disease
Discuss how evolving clinical trial designs and emerging biomarkers will redefine evaluation of efficacy and target engagement in preclinical models